2018
Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions
Caniglia EC, Phillips A, Porter K, Sabin CA, Winston A, Logan R, Gill J, Vandenhende MA, Barger D, Lodi S, Moreno S, Arribas JR, Pacheco A, Cardoso SW, Chrysos G, Gogos C, Abgrall S, Costagliola D, Meyer L, Seng R, van Sighem A, Reiss P, Muga R, Hoyos SP, Braun D, Hauser C, Barrufet P, Leyes M, Tate J, Justice A, Hernán MA. Commonly Prescribed Antiretroviral Therapy Regimens and Incidence of AIDS-Defining Neurological Conditions. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 77: 102-109. PMID: 28991888, PMCID: PMC5720915, DOI: 10.1097/qai.0000000000001562.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAdultAIDS Dementia ComplexAIDS-Related Opportunistic InfectionsAlkynesAmericasAtazanavir SulfateBenzoxazinesCohort StudiesCyclopropanesDarunavirEuropeFemaleHIV Protease InhibitorsHumansLeukoencephalopathy, Progressive MultifocalLopinavirMaleMeningitis, CryptococcalMiddle AgedProspective StudiesReverse Transcriptase InhibitorsToxoplasmosisConceptsNucleoside reverse transcriptase inhibitor (NRTI) backboneReverse transcriptase inhibitor backboneHazard ratioNeurological conditionsInhibitor backbonePooled logistic modelCombined end pointRespective hazard ratiosProgressive multifocal leukoencephalopathyProspective cohort studyAntiretroviral therapy regimensHIV-positive individualsHIV-CAUSAL CollaborationIncidence of AIDSCART initiationHIV dementiaAntiretroviral therapyCART regimenCryptococcal meningitisMultifocal leukoencephalopathyClinical characteristicsCohort studyTherapy regimensAtazanavirLopinavir
2014
Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions
Caniglia EC, Cain LE, Justice A, Tate J, Logan R, Sabin C, Winston A, van Sighem A, Miro JM, Podzamczer D, Olson A, Arribas JR, Moreno S, Meyer L, del Romero J, Dabis F, Bucher HC, Wandeler G, Vourli G, Skoutelis A, Lanoy E, Gasnault J, Costagliola D, Hernán MA. Antiretroviral penetration into the CNS and incidence of AIDS-defining neurologic conditions. Neurology 2014, 83: 134-141. PMID: 24907236, PMCID: PMC4117168, DOI: 10.1212/wnl.0000000000000564.Peer-Reviewed Original ResearchConceptsHigher CPE scoreLower CPE scoreAntiretroviral therapy regimenProgressive multifocal leukoencephalopathyCPE scoreHIV dementiaHazard ratioCryptococcal meningitisMultifocal leukoencephalopathyTherapy regimenAntiretroviral therapy-naive individualsCNS penetration-effectiveness (CPE) scoreTherapy-naive individualsRespective hazard ratiosCases of toxoplasmosisHIV-CAUSAL CollaborationIncidence of AIDSAntiretroviral penetrationAntiretroviral regimenBaseline regimensInitial regimenNeurologic conditionsNeurologic disordersCNS penetrationRegimen